The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Phase III trial of trastuzumab rezetecan vs SOC in HER2-positive advanced CRC
Filippo Pietrantonio, MD, Fonzdazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, highlights results from a Phase III trial (NCT06199973) of trastuzumab rezetecan, a HER2-targeted antibody-drug conjugate (ADC), versus standard of care in patients with chemotherapy-refractory, HER2-positive, RAS and RAF wild-type advanced colorectal cancer (CRC). Trastuzumab rezetecan demonstrated significantly prolonged progression-free survival and improved overall response rate versus standard of care, with a manageable safety profile. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
